Welsh, Carson, Anderson & Stowe Commits Up to $250 Million in New Cell and Gene Therapy Investing Platform

McGuireWoods LLP
Contact

Welsh, Carson, Anderson & Stowe (WCAS) has announced it is committing up to $250 million to a newly formed platform that will invest in non-therapeutic companies supporting cell and gene therapy.

The platform — named Kiniciti and based in New York — plans to invest in a cross section of cell and gene therapy opportunities across multiple geographies.

WCAS, based in New York, is a private equity firm focused exclusively on the healthcare and technology industries. Founded in 1979, the firm targets growth-oriented companies with an investment strategy that is deal-size agnostic.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McGuireWoods LLP | Attorney Advertising

Written by:

McGuireWoods LLP
Contact
more
less

McGuireWoods LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.